A new statement, endorsed by IMS, reviews the ‘Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer’
A new position paper has published online in the Journal of Bone Oncology and endorsed by IMS and other International Societies including IOF, CABS, ECTS, ESCEO, IEG, IMS and SIGO JBO. This provides an updated algorithm to better assess fracture risk and direct treatment in the management of AI-associated bone loss (AIBL).
Mary Ann Lumsden, President of IMS comments “Decreased bone density and fracture are a major issue for women taking aromatase inhibitors for treatment of breast cancer. Risk of fracture increases substantially and this will only get worse as the women age. This document highlights the importance of bone loss and suggests practical measures for treatment that are endorsed by several societies interested in diseases of bone from around the world. Hopefully, this means that in the future, this problem will not be neglected and women will be monitored for bone loss and receive appropriate treatment at the right time.”
The Journal of Bone Oncology is an open access journal which makes the paper easily available- just follow the link belowhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384888
